Holen Sie sich die Stockscreener-App
82.95
1.97%
1.795
Handel nachbörslich:
82.81
-0.145
-0.17%
Schlusskurs vom Vortag:
$81.16
Offen:
$82.24
24-Stunden-Volumen:
363.50K
Relative Volume:
0.42
Marktkapitalisierung:
$6.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.62M
KGV:
-19.17
EPS:
-4.3278
Netto-Cashflow:
$-235.37M
1W Leistung:
+5.74%
1M Leistung:
-3.33%
6M Leistung:
+17.57%
1J Leistung:
+109.63%
1-Tages-Spanne:
$81.08
$84.66
1-Wochen-Bereich:
$75.00
$84.66
52-Wochen-Spanne:
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
82.80 | 6.12B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Hold |
| 2026-01-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-12-17 | Eingeleitet | Stephens | Overweight |
| 2025-12-10 | Eingeleitet | Deutsche Bank | Buy |
| 2025-11-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-07 | Bestätigt | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
APGE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Certain Stock Options of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2026. - marketscreener.com
BofA Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $131 - Moomoo
Apogee Therapeutics: Targeting Atopic Dermatitis (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics Insider Sold Shares Worth $1,641,711, According to a Recent SEC Filing - Moomoo
How (APGE) Movements Inform Risk Allocation Models - Stock Traders Daily
How Investors Are Reacting To Apogee Therapeutics (APGE) Trial Win Amid Wider Losses And Insider Sales - simplywall.st
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock - Investing.com
Apogee Therapeutics (APGE) CEO sells 20,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics, Inc.Common Stock (NQ: APGE - FinancialContent
Jefferies raises Apogee Therapeutics stock price target on trial outlook By Investing.com - Investing.com Nigeria
Jefferies raises Apogee Therapeutics stock price target on trial outlook - Investing.com
Form 144 | Apogee Therapeutics(APGE.US) Officer Proposes to Sell 4.95 Million in Common Stocks - Moomoo
APGE (APGE) Form 144: Insider-related sale notices, 60,000 shares planned - Stock Titan
Apogee Therapeutics (APGE) Gets a Buy from Wedbush - The Globe and Mail
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $100 to $137 - Moomoo
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $130 - Moomoo
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - 富途牛牛
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating - Moomoo
Apogee Therapeutics Q1 2026 10-Q: Financial Results, Key Risks, and Forward-Looking Statements - Minichart
Apogee Therapeutics (NASDAQ:APGE) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Apogee Therapeutics Reports Strong Q1 2026 Results and Pipeline Progress for Zumilokibart in Atopic Dermatitis and Asthma 12 - Minichart
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Apogee Therapeutics Q1 Net Loss Widens - Moomoo
Apogee Therapeutics 1Q 2026: Net loss $(74.1M), No product revenue — 10-Q Summary - TradingView
Apogee Therapeutics (NASDAQ: APGE) reports cash runway and Phase 2 AD data - Stock Titan
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, vs. FactSet Est of $74.2M - marketscreener.com
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, Vs. FactSet Est of $74.2M - Moomoo
Apogee Therapeutics (Nasdaq: APGE) Q1 loss widens, cash runway to 2029 - Stock Titan
Apogee's AD drug zumilokibart keeps 52-week response with 3- and 6-month dosing - Stock Titan
Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results - Moomoo
Apogee Therapeutics Insider Sold Shares Worth $462,784, According to a Recent SEC Filing - marketscreener.com
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics CMO Dambkowski sells $462,784 in shares By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Dambkowski sells $462,784 in shares - Investing.com India
Apogee Therapeutics (APGE) CMO sells 5,500 shares, exercises 4,125 options - Stock Titan
Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation - MSN
Trading Systems Reacting to (APGE) Volatility - Stock Traders Daily
Insider to sell 22,000 shares at APGE (NASDAQ: APGE) after 11,000 sold - Stock Titan
Should Zumilokibart’s Phase 2 Data and Insider Sales Activity Require Action From Apogee Therapeutics (APGE) Investors? - Sahm
CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henderson Jane - Moomoo
Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn - MarketBeat
Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC) and Apogee Therapeutics (APGE) - The Globe and Mail
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):